<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01689805</url>
  </required_header>
  <id_info>
    <org_study_id>FLG-255-AR</org_study_id>
    <nct_id>NCT01689805</nct_id>
  </id_info>
  <brief_title>Clinical Importance of Filaggrin Gene Mutation for Treatment Outcome in Atopic Dermatitis</brief_title>
  <official_title>Do Mutations in the Filaggrin Gene Have Clinical Importance for the Treatment Outcome in Atopic Dermatitis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis is a common disease which affects about one million people in Finland at&#xD;
      some stage of their life. In atopic dermatitis we see a superficial inflammation of the skin&#xD;
      and a defect in skin barrier function. The filaggrin protein plays a central role in the skin&#xD;
      barrier function and studies indicate that about 30% of patients with atopic dermatitis have&#xD;
      a mutation in the filaggrin gene. The aim of the study is to investigate whether a mutation&#xD;
      in the filaggrin gene affects the clinical treatment outcome in patients with atopic&#xD;
      dermatitis. If a mutation predisposes to a worse response to treatment, this could be&#xD;
      examined and those patients with the mutation could be given extra treatment support for&#xD;
      their atopic dermatitis. The prevalence of filaggrin mutation in the Finnish non-atopic&#xD;
      population is studied in the control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Filaggrin mutation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgE</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Patients with atopic dermatitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-atopic controls</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples are collected to investigate if the patient has a mutation in the filaggrin&#xD;
      gene.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atopic dermatitis who are followed-up at the Skin and Allergy Hospital in&#xD;
        Helsinki for at least one year can be included in the study.&#xD;
&#xD;
        The control population consists of non-atopic persons without any other skin disease&#xD;
        (samples for the control population are applied for from a sample collection of the&#xD;
        National institute for health and welfare).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (patients with atopic dermatitis):&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  Clinical diagnosis of atopic dermatitis&#xD;
&#xD;
          -  Need for follow-up at the Skin and Allergy Hospital&#xD;
&#xD;
          -  Patient gives signed informed consent to participate in this study&#xD;
&#xD;
          -  Patients parents and grandparents are of Finnish origin&#xD;
&#xD;
        Inclusion Criteria (Controls):&#xD;
&#xD;
          -  No history of atopy or skin disease&#xD;
&#xD;
          -  Age at least 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Remitz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin and Allergy Hospital, Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anita Remitz, MD, PhD</last_name>
    <phone>+358-9-4711</phone>
    <email>anita.remitz@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skin and Allergy Hospital, Departments of Dermatology and Clinical Genetics</name>
      <address>
        <city>Helsinki</city>
        <zip>PB 160</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Remitz, MD, PhD</last_name>
      <email>anita.remitz@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Anita Remitz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sakari Reitamo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanna M Mandelin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ville Kiiski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minna Pöyhönen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eveliina Salminen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sirpa Kivirikko, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>September 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Anita Remitz</investigator_full_name>
    <investigator_title>MD, PhD, Specialist in Dermatology</investigator_title>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Filaggrin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

